Officer of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently purchased 20,000 shares of the company's common stock. The shares were acquired at a price of $2.2828 each, totaling $45,656.

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

Here is a detailed guide about all the latest changes introduced as experimental features in Minecraft 1.21.60 drop for ...

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

In this installment, I primarily discuss considerations to keep in mind when choosing buffering additives that will be used ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...